drugset / Trial / NCT00053482

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

NCT00053482

Phase 2 Completed 357 enrolled Emergent BioSolutions
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.

Timeline

Start
2003-01
Primary completion
2003-04
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM2000 Vaccine 1e-08 unknown
Subject ACAM2000 Vaccine 1e-07 unknown
Subject ACAM2000 Vaccine 2e-07 unknown
Subject ACAM2000 Vaccine 5e-06 unknown
Comparator Vaccinia virus (calf lymph) smallpox vaccine Vaccine 1e-08 unknown

Indications